Symbols / AMRX Stock $12.83 -0.31% Amneal Pharmaceuticals, Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NMS
AMRX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Mr. Chirag K. Patel
Exch · Country NMS · United States
Market Cap 4.09B
Enterprise Value 6.52B
Income 72.06M
Sales 3.02B
FCF (ttm) 197.07M
Book/sh -0.23
Cash/sh 0.91
Employees 8,700
Insider 10d —
IPO May 07, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 58.32
Forward P/E 10.84
PEG —
P/S 1.36
P/B -57.02
P/C —
EV/EBITDA 10.11
EV/Sales 2.16
Quick Ratio 1.39
Current Ratio 2.17
Debt/Eq 45,095.52
LT Debt/Eq —
EPS (ttm) 0.22
EPS next Y 1.18
EPS Growth —
Revenue Growth 11.50%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-04
Earnings (prior) 2026-02-27
ROA 7.32%
ROE —
ROIC —
Gross Margin 37.38%
Oper. Margin 14.06%
Profit Margin 2.39%
Shs Outstand 319.00M
Shs Float 176.28M
Insider Own 44.04%
Instit Own 49.54%
Short Float 4.13%
Short Ratio 4.74
Short Interest 8.56M
52W High 15.42
vs 52W High -16.80%
52W Low 7.02
vs 52W Low 82.76%
Beta 1.32
Impl. Vol. 28.25%
Rel Volume 0.66
Avg Volume 1.95M
Volume 1.29M
Target (mean) $17.00
Tgt Median $17.00
Tgt Low $15.00
Tgt High $19.00
# Analysts 5
Recom Strong_buy
Prev Close $12.87
Price $12.83
Change -0.31%
About

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$17.00
Mean price target
2. Current target
$12.83
Latest analyst target
3. DCF / Fair value
$11.12
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$12.83
Low
$15.00
High
$19.00
Mean
$17.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-17 init UBS — → Buy $19
2026-03-02 main Truist Securities Buy → Buy $17
2025-12-09 init Barclays — → Overweight $15
2025-10-31 reit Piper Sandler Overweight → Overweight $13
2025-09-16 main JP Morgan Overweight → Overweight $14
2025-03-03 main Barclays Overweight → Overweight $11
2025-02-24 up JP Morgan Neutral → Overweight $12
2024-11-11 main Piper Sandler Overweight → Overweight $11
2024-10-02 main Truist Securities Buy → Buy $12
2024-09-06 up JP Morgan Underweight → Neutral $9
2024-08-13 main Barclays Overweight → Overweight $10
2024-08-12 main Truist Securities Buy → Buy $10
2024-05-06 main Goldman Sachs Buy → Buy $8
2024-05-06 reit Truist Securities Buy → Buy $9
2024-03-21 main Piper Sandler Overweight → Overweight $8
2024-03-04 main Goldman Sachs Buy → Buy $6
2024-01-29 main Barclays Overweight → Overweight $8
2023-11-08 main Truist Securities Buy → Buy $7
2023-09-06 reit Truist Securities Buy → Buy $6
2023-08-07 main Piper Sandler Overweight → Overweight $5
News
RSS: Latest AMRX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-04 BOYER ANDREW S Officer — 548,953 — —
2026-03-04 PATEL CHIRAG K Chief Executive Officer — 886,468 — —
2026-03-04 SHAH NIKITA Officer — 508,499 — —
2026-03-04 PATEL CHINTU Chief Executive Officer — 886,468 — —
2026-03-04 DALY JASON B. Officer — 426,819 — —
2026-03-04 KONIDARIS TASOS Chief Financial Officer — 633,865 — —
2025-11-17 NARK THEODORE C. Director — 50,000 $11.72 $586,000
2025-11-12 SHAH NIKITA Officer — 131,856 $11.92 $1,571,724
2025-11-12 SHAH NIKITA Officer — 131,856 $2.75 $362,604
2025-08-27 KIELY JOHN J. Director — 32,000 $9.23 $295,360
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
3,018.76
+8.05%
2,793.96
+16.73%
2,393.61
+8.20%
2,212.30
Operating Revenue
3,018.76
+8.05%
2,793.96
+16.73%
2,393.61
+8.20%
2,212.30
Cost Of Revenue
1,905.45
+7.44%
1,773.52
+12.74%
1,573.04
+10.19%
1,427.60
Reconciled Cost Of Revenue
1,905.45
+7.44%
1,773.52
+12.74%
1,573.04
+10.19%
1,427.60
Gross Profit
1,113.31
+9.10%
1,020.44
+24.36%
820.57
+4.57%
784.71
Operating Expense
715.39
+6.45%
672.07
+15.51%
581.82
-2.34%
595.79
Research And Development
193.81
-1.40%
196.56
+17.15%
167.78
-16.13%
200.05
Selling General And Administration
526.83
+10.58%
476.44
+10.88%
429.68
+7.50%
399.70
Other Operating Expenses
-5.24
-463.44%
-0.93
+94.05%
-15.63
-294.82%
-3.96
Total Expenses
2,620.85
+7.17%
2,445.58
+13.49%
2,154.86
+6.50%
2,023.38
Operating Income
397.91
+14.22%
348.37
+45.92%
238.75
+26.37%
188.92
Total Operating Income As Reported
394.10
+58.06%
249.33
+21.99%
204.37
+315.29%
-94.93
EBITDA
603.87
+37.31%
439.77
+10.01%
399.76
+165.75%
150.43
Normalized EBITDA
606.64
+1.73%
596.35
+36.91%
435.58
-2.61%
447.27
Reconciled Depreciation
223.57
-5.34%
236.19
+2.96%
229.40
-4.49%
240.18
EBIT
380.30
+86.80%
203.58
+19.50%
170.36
+289.82%
-89.75
Total Unusual Items
-2.77
+98.23%
-156.57
-337.04%
-35.83
+87.93%
-296.85
Total Unusual Items Excluding Goodwill
-2.77
+98.23%
-156.57
-337.04%
-35.83
+87.93%
-296.85
Special Income Charges
-10.41
+93.05%
-149.73
-299.30%
-37.50
+86.82%
-284.48
Other Special Charges
6.20
-95.79%
147.37
+312.25%
35.75
-87.31%
281.62
Restructuring And Mergern Acquisition
4.21
+78.68%
2.35
+34.65%
1.75
-38.87%
2.86
Net Income
72.06
+161.65%
-116.89
-39.16%
-83.99
+35.38%
-129.99
Pretax Income
139.21
+353.05%
-55.01
-36.61%
-40.27
+83.77%
-248.13
Net Non Operating Interest Income Expense
-272.46
-5.36%
-258.60
-2.85%
-251.43
-58.47%
-158.67
Interest Expense Non Operating
241.09
-6.77%
258.60
+22.77%
210.63
+32.99%
158.38
Net Interest Income
-272.46
-5.36%
-258.60
-2.85%
-251.43
-58.47%
-158.67
Interest Expense
241.09
-6.77%
258.60
+22.77%
210.63
+32.99%
158.38
Other Income Expense
13.75
+109.50%
-144.79
-424.93%
-27.58
+90.09%
-278.38
Other Non Operating Income Expenses
16.52
+40.23%
11.78
+42.93%
8.24
-55.36%
18.46
Gain On Sale Of Security
7.63
+211.52%
-6.85
-509.69%
1.67
+113.52%
-12.36
Gain On Sale Of Business
—
—
—
0.00
Tax Provision
11.28
-40.22%
18.86
+123.18%
8.45
+26.87%
6.66
Tax Rate For Calcs
0.00
-61.43%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-0.22
+99.32%
-32.88
-337.04%
-7.52
+87.93%
-62.34
Net Income Including Noncontrolling Interests
127.93
+273.17%
-73.88
-51.63%
-48.72
+80.88%
-254.79
Net Income From Continuing Operation Net Minority Interest
72.06
+161.65%
-116.89
-39.16%
-83.99
+35.38%
-129.99
Net Income From Continuing And Discontinued Operation
72.06
+161.65%
-116.89
-39.16%
-83.99
+35.38%
-129.99
Net Income Continuous Operations
127.93
+273.17%
-73.88
-51.63%
-48.72
+80.88%
-254.79
Minority Interests
-55.88
-29.91%
-43.01
-21.94%
-35.27
-128.26%
124.80
Normalized Income
74.60
+996.04%
6.81
+112.22%
-55.69
-153.28%
104.52
Net Income Common Stockholders
72.06
+161.65%
-116.89
-39.16%
-83.99
+35.38%
-129.99
Diluted EPS
0.22
+157.89%
-0.38
+20.83%
-0.48
+44.19%
-0.86
Basic EPS
0.23
+160.53%
-0.38
+20.83%
-0.48
+44.19%
-0.86
Basic Average Shares
313.37
+1.42%
308.98
+75.42%
176.14
+16.69%
150.94
Diluted Average Shares
324.81
+5.12%
308.98
+75.42%
176.14
+16.69%
150.94
Diluted NI Availto Com Stockholders
72.06
+161.65%
-116.89
-39.16%
-83.99
+35.38%
-129.99
Other Taxes
—
50.68
+1522.28%
3.12
+395.09%
0.63
Total Other Finance Cost
31.36
—
40.80
+13922.34%
0.29
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
3,678.28
+5.05%
3,501.45
+0.83%
3,472.57
-8.60%
3,799.34
Current Assets
1,911.18
+20.37%
1,587.81
+15.24%
1,377.86
-2.41%
1,411.82
Cash Cash Equivalents And Short Term Investments
282.03
+155.11%
110.55
+20.77%
91.54
+252.41%
25.98
Cash And Cash Equivalents
282.03
+155.11%
110.55
+20.77%
91.54
+252.41%
25.98
Receivables
939.87
+16.24%
808.56
+25.23%
645.66
-18.98%
796.91
Accounts Receivable
895.14
+15.39%
775.73
+26.40%
613.73
-17.26%
741.79
Gross Accounts Receivable
1,740.32
+33.48%
1,303.79
+8.65%
1,199.98
-10.78%
1,344.96
Allowance For Doubtful Accounts Receivable
-845.18
-60.05%
-528.06
+9.93%
-586.25
+2.81%
-603.17
Other Receivables
25.60
+64.94%
15.52
-12.83%
17.80
-57.34%
41.74
Taxes Receivable
18.66
+10.89%
16.83
+27.80%
13.17
+2.23%
12.88
Inventory
606.30
-1.00%
612.45
+5.34%
581.38
+9.54%
530.74
Raw Materials
227.35
+9.46%
207.70
-4.61%
217.74
-3.06%
224.61
Work In Process
55.45
+4.96%
52.84
-11.30%
59.56
+1.78%
58.52
Finished Goods
323.49
-8.08%
351.92
+15.73%
304.08
+22.81%
247.61
Prepaid Assets
54.13
+11.92%
48.37
-6.47%
51.71
+5.65%
48.95
Restricted Cash
28.84
+266.57%
7.87
+4.01%
7.57
-18.23%
9.25
Total Non Current Assets
1,767.10
-7.66%
1,913.64
-8.64%
2,094.71
-12.26%
2,387.52
Net PPE
550.33
+5.09%
523.69
-4.81%
550.14
-6.66%
589.36
Gross PPE
1,156.50
+6.37%
1,087.21
+2.75%
1,058.16
+2.21%
1,035.33
Accumulated Depreciation
-606.17
-7.57%
-563.52
-10.92%
-508.03
-13.91%
-445.97
Properties
0.00
0.00
0.00
0.00
Land And Improvements
19.69
+142.73%
8.11
-10.11%
9.02
-15.71%
10.71
Buildings And Improvements
234.60
+4.43%
224.66
-1.40%
227.84
+0.98%
225.63
Machinery Furniture Equipment
568.09
+3.94%
546.56
+4.18%
524.61
+8.07%
485.44
Construction In Progress
92.91
+18.81%
78.20
+15.57%
67.67
-2.42%
69.34
Other Properties
107.38
+8.70%
98.78
-3.68%
102.56
-14.21%
119.55
Leases
133.83
+2.24%
130.91
+3.51%
126.46
+1.44%
124.67
Goodwill And Other Intangible Assets
1,158.97
-12.85%
1,329.81
-10.69%
1,489.05
-12.15%
1,694.95
Goodwill
595.47
-0.33%
597.44
-0.20%
598.63
-0.04%
598.85
Other Intangible Assets
563.50
-23.06%
732.38
-17.75%
890.42
-18.76%
1,096.09
Non Current Deferred Assets
5.20
+84.29%
2.82
-36.30%
4.43
+100.68%
2.21
Non Current Prepaid Assets
37.55
+133.01%
16.11
+134.39%
6.88
-4.96%
7.23
Other Non Current Assets
9.30
+76.30%
5.28
-25.93%
7.13
-13.00%
8.19
Total Liabilities Net Minority Interest
3,749.61
+3.84%
3,610.96
+4.59%
3,452.56
-4.50%
3,615.36
Current Liabilities
881.63
-21.96%
1,129.77
+33.45%
846.60
+12.46%
752.80
Payables And Accrued Expenses
736.91
+7.61%
684.80
+45.44%
470.86
-3.24%
486.64
Payables
310.16
+10.38%
281.00
+74.41%
161.12
-9.83%
178.69
Accounts Payable
254.67
-1.55%
258.69
+80.18%
143.57
-13.50%
165.98
Other Payable
—
10.23
+0.00%
10.23
+0.00%
10.23
Current Accrued Expenses
426.76
+5.69%
403.80
+30.37%
309.74
+0.58%
307.95
Employee Benefits
11.35
-33.70%
17.12
-19.54%
21.28
+27.16%
16.74
Pensionand Other Post Retirement Benefit Plans Current
79.89
+9.49%
72.96
+2.58%
71.12
+31.61%
54.04
Total Tax Payable
—
—
—
0.36
Current Debt And Capital Lease Obligation
21.58
-93.66%
340.25
+49.48%
227.62
+117.53%
104.64
Current Debt
6.76
-97.91%
324.21
+52.12%
213.12
+136.91%
89.96
Other Current Borrowings
6.76
-96.98%
224.21
+557.03%
34.12
+13.90%
29.96
Current Capital Lease Obligation
14.81
-7.65%
16.04
+10.64%
14.50
-1.22%
14.68
Other Current Liabilities
43.26
+36.22%
31.75
-58.75%
76.99
-28.37%
107.48
Total Non Current Liabilities Net Minority Interest
2,867.98
+15.59%
2,481.19
-4.79%
2,605.96
-8.96%
2,862.56
Long Term Debt And Capital Lease Obligation
2,667.47
+18.40%
2,252.88
-10.70%
2,522.90
-7.94%
2,740.50
Long Term Debt
2,565.11
+18.66%
2,161.79
-10.94%
2,427.45
-7.76%
2,631.69
Long Term Capital Lease Obligation
102.36
+12.36%
91.09
-4.56%
95.45
-12.28%
108.81
Tradeand Other Payables Non Current
0.00
-100.00%
1.25
+151.91%
0.50
-11.72%
0.56
Other Non Current Liabilities
92.73
-1.41%
94.05
+1044.87%
8.21
-88.29%
70.17
Preferred Securities Outside Stock Equity
77.29
+18.96%
64.97
+57.35%
41.29
+65.51%
24.95
Stockholders Equity
-70.79
+35.21%
-109.27
-652.38%
19.78
-93.37%
298.42
Common Stock Equity
-70.79
+35.21%
-109.27
-652.38%
19.78
-93.37%
298.42
Capital Stock
3.15
+1.52%
3.10
+1.08%
3.07
+0.99%
3.04
Common Stock
3.15
+1.52%
3.10
+1.08%
3.07
+0.99%
3.04
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
314.56
+1.51%
309.88
+1.08%
306.56
+102.37%
151.49
Ordinary Shares Number
314.56
+1.51%
309.88
+1.08%
306.56
+102.37%
151.49
Additional Paid In Capital
571.79
+2.07%
560.21
+3.89%
539.24
-22.03%
691.63
Retained Earnings
-535.00
+11.87%
-607.06
-23.85%
-490.18
-20.68%
-406.18
Gains Losses Not Affecting Retained Earnings
-110.73
-69.03%
-65.51
-102.51%
-32.35
-425.48%
9.94
Minority Interest
-0.54
-118.37%
-0.24
-206.52%
0.23
+100.20%
-114.44
Other Equity Adjustments
-110.73
-69.03%
-65.51
-102.51%
-32.35
-425.48%
9.94
Total Equity Gross Minority Interest
-71.33
+34.87%
-109.51
-647.26%
20.01
-89.12%
183.98
Total Capitalization
2,494.32
+21.52%
2,052.52
-16.13%
2,447.23
-16.48%
2,930.11
Working Capital
1,029.55
+124.77%
458.04
-13.78%
531.27
-19.38%
659.02
Invested Capital
2,501.08
+5.23%
2,376.74
-10.66%
2,660.36
-11.91%
3,020.07
Total Debt
2,689.05
+3.70%
2,593.14
-5.72%
2,750.52
-3.33%
2,845.14
Net Debt
2,289.85
-3.60%
2,375.45
-6.81%
2,549.03
-5.44%
2,695.67
Capital Lease Obligations
117.17
+9.37%
107.14
-2.56%
109.95
-10.96%
123.49
Net Tangible Assets
-1,229.76
+14.55%
-1,439.08
+2.05%
-1,469.27
-5.21%
-1,396.53
Tangible Book Value
-1,229.76
+14.55%
-1,439.08
+2.05%
-1,469.27
-5.21%
-1,396.53
Derivative Product Liabilities
—
—
—
0.00
Duefrom Related Parties Current
0.47
-2.89%
0.48
-49.32%
0.95
+91.00%
0.50
Dueto Related Parties Current
55.48
+148.69%
22.31
+204.75%
7.32
+195.32%
2.48
Dueto Related Parties Non Current
19.13
-62.41%
50.90
+332.24%
11.78
+22.04%
9.65
Financial Assets
5.76
-83.98%
35.92
-3.15%
37.09
-56.66%
85.59
Interest Payable
18.66
+1077.48%
1.58
—
—
Line Of Credit
0.00
-100.00%
100.00
-44.13%
179.00
+198.33%
60.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
339.99
+15.21%
295.10
-14.61%
345.58
+430.84%
65.10
Cash Flow From Continuing Operating Activities
339.99
+15.21%
295.10
-14.61%
345.58
+430.84%
65.10
Net Income From Continuing Operations
127.93
+273.17%
-73.88
-51.63%
-48.72
+80.88%
-254.79
Depreciation Amortization Depletion
223.57
-5.34%
236.19
+2.96%
229.40
-4.49%
240.18
Depreciation
—
—
66.20
-2.81%
68.11
Amortization Cash Flow
—
—
163.20
-5.15%
172.06
Depreciation And Amortization
223.57
-5.34%
236.19
+2.96%
229.40
-4.49%
240.18
Amortization Of Intangibles
—
—
163.20
-5.15%
172.06
Other Non Cash Items
59.76
+1253.50%
4.42
-90.06%
44.41
+154.59%
17.45
Stock Based Compensation
31.95
+15.07%
27.77
+3.53%
26.82
-15.78%
31.85
Provisionand Write Offof Assets
85.96
-10.97%
96.56
+29.29%
74.69
+46.17%
51.10
Asset Impairment Charge
22.78
+2376.52%
0.92
-98.63%
66.93
+177.95%
24.08
Deferred Tax
—
—
—
—
Deferred Income Tax
—
—
—
—
Operating Gains Losses
-7.45
-203.64%
7.19
+1036.33%
-0.77
-105.06%
15.19
Net Foreign Currency Exchange Gain Loss
-7.45
-203.64%
7.19
+1036.33%
-0.77
-105.06%
15.19
Gain Loss On Sale Of PPE
—
—
—
—
Change In Working Capital
-204.52
-4927.43%
-4.07
+91.38%
-47.19
+21.28%
-59.95
Change In Receivables
-120.58
+25.64%
-162.16
-228.90%
125.80
+259.10%
-79.07
Changes In Account Receivables
-120.57
+25.87%
-162.64
-228.78%
126.29
+258.42%
-79.72
Change In Inventory
-87.03
+33.33%
-130.53
-3.45%
-126.18
-23.23%
-102.40
Change In Prepaid Assets
-19.16
-1898.23%
-0.96
-102.54%
37.81
+282.66%
9.88
Change In Payables And Accrued Expense
22.25
-92.32%
289.58
+442.22%
-84.62
-175.79%
111.64
Change In Payable
22.25
-92.32%
289.58
+442.22%
-84.62
-175.79%
111.64
Change In Account Payable
21.32
-90.93%
235.13
+348.96%
-94.45
-186.20%
109.57
Investing Cash Flow
-112.26
-78.21%
-63.00
+8.95%
-69.19
+60.31%
-174.31
Cash Flow From Continuing Investing Activities
-112.26
-78.21%
-63.00
+8.95%
-69.19
+60.31%
-174.31
Net PPE Purchase And Sale
-96.75
-60.34%
-60.34
-28.93%
-46.80
+4.09%
-48.80
Purchase Of PPE
-98.84
-63.81%
-60.34
-28.93%
-46.80
+4.09%
-48.80
Sale Of PPE
2.09
0.00
0.00
—
Capital Expenditure
-114.36
-52.50%
-74.99
-8.38%
-69.19
+23.63%
-90.59
Net Business Purchase And Sale
0.00
-100.00%
11.99
0.00
+100.00%
-84.71
Purchase Of Business
—
0.00
0.00
+100.00%
-84.71
Gain Loss On Sale Of Business
—
—
—
0.00
Net Intangibles Purchase And Sale
-15.51
-5.90%
-14.65
+34.56%
-22.39
+46.44%
-41.80
Purchase Of Intangibles
-15.51
-5.90%
-14.65
+34.56%
-22.39
+46.44%
-41.80
Net Other Investing Changes
—
—
—
1.00
Financing Cash Flow
-31.53
+85.11%
-211.79
+0.37%
-212.57
-99.37%
-106.62
Cash Flow From Continuing Financing Activities
-31.53
+85.11%
-211.79
+0.37%
-212.57
-99.37%
-106.62
Net Issuance Payments Of Debt
101.24
+154.69%
-185.12
-917.23%
22.65
+159.19%
-38.27
Issuance Of Debt
2,912.75
+5968.23%
48.00
-89.01%
436.73
+413.80%
85.00
Repayment Of Debt
-2,811.51
-1106.05%
-233.12
+43.70%
-414.08
-235.91%
-123.27
Long Term Debt Issuance
2,694.75
0.00
-100.00%
217.73
0.00
Long Term Debt Payments
0.00
+100.00%
-44.20
0.00
+100.00%
-123.27
Net Long Term Debt Issuance
2,694.75
+6196.72%
-44.20
-120.30%
217.73
+276.63%
-123.27
Short Term Debt Issuance
218.00
+354.17%
48.00
-78.08%
219.00
+157.65%
85.00
Short Term Debt Payments
-2,811.51
-1388.22%
-188.92
+54.38%
-414.08
—
Net Short Term Debt Issuance
-2,593.51
-1740.44%
-140.92
+27.76%
-195.08
-329.51%
85.00
Proceeds From Stock Option Exercised
1.96
+69.84%
1.15
+155.88%
0.45
-31.87%
0.66
Net Other Financing Charges
-134.73
-384.18%
-27.83
+88.19%
-235.68
-241.51%
-69.01
Changes In Cash
196.20
+865.93%
20.31
-68.17%
63.81
+129.57%
-215.83
Effect Of Exchange Rate Changes
-1.68
-68.17%
-1.00
-1636.92%
0.07
+101.14%
-5.68
Beginning Cash Position
118.42
+19.49%
99.11
+181.34%
35.23
-86.28%
256.74
End Cash Position
312.94
+164.26%
118.42
+19.49%
99.11
+181.34%
35.23
Free Cash Flow
225.63
+2.51%
220.11
-20.36%
276.39
+1184.09%
-25.50
Interest Paid Supplemental Data
197.85
-24.92%
263.52
+36.68%
192.81
+35.09%
142.72
Income Tax Paid Supplemental Data
21.33
+40.12%
15.22
+509.78%
2.50
-80.27%
12.65
Sale Of Business
0.00
-100.00%
11.99
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category